AN1
Click for more information
0.00% 0.8¢ anagenics limited

"Target Corona (COVID19) - Midkine is where the fire is coming from", page-4

  1. Pharmargeddon
    3,152 Posts.
    lightbulb Created with Sketch. 335
    clock Created with Sketch.
    01/08/20
    08:01
    Post #: 46233128
    Sorry, link does not work


    Things starting to add up

    CELLMID US, EURO MIDKINE PATENTS CELLMID Cellmid says it has received US and European patents for improved midkine antibodies, which will protect its intellectual property until October 14, 2035. ... volunteers and idiopathic pulmonary fibrosis-interstatial lung disease patients.
    Biotech back issue.

    We are OK to 2035 by the looks on this one.
    CDY Price at posting: 12.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 11  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

AWJ Auric jumps 10% on maiden cash sales in Q3CY24 and firm guidance
right-arrow Created with Sketch.
NEWS The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?
right-arrow Created with Sketch.
SXE SCEE boosts Synergy deal by $50M for Collie battery project
right-arrow Created with Sketch.
A1M Swagman shoot proves plentiful for AIC, with Cu beyond 3% close to Eloise
right-arrow Created with Sketch.
CUV British study shows Clinuvel drug effective on DNA of UV-damaged skin
right-arrow Created with Sketch.
ITM Fast-track assaying yields 182 g/t gold for iTech at new NT play
right-arrow Created with Sketch.
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
(20min delay)
Last
0.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $3.690M
Open High Low Value Volume
0.8¢ 0.8¢ 0.8¢ $384 48.04K

Buyers (Bids)

No. Vol. Price($)
1 648959 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 340000 1
View Market Depth
Last trade - 14.49pm 05/07/2024 (20 minute delay) ?
AN1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.